Myelofibrosis is being considered in the context of 2026, with a focus on matching therapy to the dominant clinical problem. The approach to myelofibrosis in 2026 appears to involve tailoring treatment to the specific clinical issue at hand. This suggests an effort to develop targeted and effective therapies for myelofibrosis.